{"filing":{"accession_number":"0001104659-26-064585","cik":"0001971387","ticker":"LIMNW","company_name":"Liminatus Pharma, Inc.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"tm2615228d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926064585/tm2615228d1_8k.htm"},"events":[{"id":9747,"run_id":8545,"accession_number":"0001104659-26-064585","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The filing discloses entry into a Merger Agreement on May 17, 2026, whereby InnocsAI LLC will merge into a newly-formed subsidiary of Liminatus Pharma, with the Company acquiring a portfolio of oncology-focused biologic and cellular therapy programs (including CAR-T and antibody candidates). The consideration is 1.6 billion shares at $0.20 per share plus contingent value rights tied to future strategic exits. This is a material acquisition transaction requiring stockholder approval and SEC registration, clearly falling under Item 1.01 (Entry into Material Definitive Agreement) and the ma_activity event type.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":537,"accession_number":"0001104659-26-064585","item_number":"1.01","item_title":"Entry into Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a Merger Agreement on May 17, 2026, whereby InnocsAI LLC will merge into a newly-formed subsidiary of Liminatus Pharma, with the Company acquiring a portfolio of oncology-focused biologic and cellular therapy programs (including CAR-T and antibody candidates). The consideration is 1.6 billion shares at $0.20 per share plus contingent value rights tied to future strategic exits. This is a material acquisition transaction requiring stockholder approval and SEC registration, clearly falling under Item 1.01 (Entry into Material Definitive Agreement) and the ma_activity event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:43:51.890622+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":537,"accession_number":"0001104659-26-064585","item_number":"1.01","item_title":"Entry into Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a Merger Agreement on May 17, 2026, whereby InnocsAI LLC will merge into a newly-formed subsidiary of Liminatus Pharma, with the Company acquiring a portfolio of oncology-focused biologic and cellular therapy programs (including CAR-T and antibody candidates). The consideration is 1.6 billion shares at $0.20 per share plus contingent value rights tied to future strategic exits. This is a material acquisition transaction requiring stockholder approval and SEC registration, clearly falling under Item 1.01 (Entry into Material Definitive Agreement) and the ma_activity event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:43:51.890622+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-05-20"}]}